Results 121 to 130 of about 1,506 (153)

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. [PDF]

Allergy
de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, de Graaf M, van Wijk F, Bakker DS, Weidinger S.   +9 more
europepmc   +1 more source

<i>In vitro</i> potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb. [PDF]

J Allergy Clin Immunol Glob
Zhu E, Prentice H, Oh J, Shaheen H, Gandhi NA, Wickman G, Dabora R, Dambkowski CL, Dillinger L.   +8 more
europepmc   +1 more source

Early Experience of Lebrikizumab▼ in the Treatment of Atopic Dermatitis

EMJ Dermatology
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lebrikizumab for the treatment of asthma

Expert Opinion on Investigational Drugs, 2016
In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain inflammation pathways and lebrikizumab an anti ...
Sabina Antoniu
exaly   +3 more sources

Lebrikizumab in the treatment of asthma

Expert Opinion on Biological Therapy, 2016
Severe asthma continues to be a major clinical problem despite the availability of effective asthma medications such as inhaled corticosteroids. Several targeted biologic therapies are emerging to treat patients with severe asthma. Areas Covered: This review provides an update of information on lebrikizumab, a novel monoclonal antibody that targets IL ...
Nicola Hanania, Amit Parulekar
exaly   +3 more sources

Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review

Annals of Pharmacotherapy
Background: Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-severe AD in patients aged ≥12 years.
Steven Feldman
exaly   +3 more sources

Lebrikizumab Treatment in Adults with Asthma

New England Journal of Medicine, 2011
Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype.
Naveen, Dutt, Prasanta R, Mohapatra, Varinder, Saini   +2 more
openaire   +6 more sources